Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Positron Emission Tomography01:29

Positron Emission Tomography

7.7K
Positron emission tomography (PET) is a medical imaging technique involving radiopharmaceuticals — substances that emit short-lived radiation. Although the first PET scanner was introduced in 1961, it took 15 more years before radiopharmaceuticals were combined with the technique and revolutionized its potential.
One of the main requirements of a PET scan is a positron-emitting radioisotope, which is produced in a cyclotron and then attached to a substance used by the part of the body...
7.7K
Imaging Studies II: Positron Emission Tomography and Scintigraphy01:25

Imaging Studies II: Positron Emission Tomography and Scintigraphy

627
Positron Emission Tomography (PET) is a medical imaging technique that provides crucial insights into the body's physiological functions at a molecular level. It is an indispensable resource for diagnosing, staging, and monitoring various illnesses, notably cancer, neurological disorders, and cardiovascular conditions.
Fundamental Principles of PET
627

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Study on the anti-inflammatory effects and mechanisms of gentisic acid based on the LPS-induced RAW264.7 cell inflammation model and the oxazolone-induced zebrafish inflammation model.

Frontiers in pharmacology·2026
Same author

Sex Differences in the Burden of Atrial Fibrillation/Flutter and Associated Heart Failure Stratified by Age at Onset.

Pacing and clinical electrophysiology : PACE·2026
Same author

Instantaneous Lipid Profiling in Rat Cerebrospinal Fluid via a Nanoconfined Sampling Extraction and Grouping Separation Integrated System: Overcoming Ex Vivo Degradation.

Analytical chemistry·2026
Same author

Bioengineered titanium implants functionalized with aptamer-valproic acid conjugates orchestrate macrophage programming and mesenchymal stem cell homing for improved osseointegration.

Bioactive materials·2026
Same author

Finerenone vs. spironolactone to reduce adverse outcomes in patients with cardiac-kidney-metabolic syndrome complicated by atrial fibrillation: findings from the Tianjin atrial fibrillation project.

European heart journal open·2026
Same author

Discovery of Highly Potent and Selective SOS1 Inhibitors for the Treatment of KRAS-Driven Colorectal Cancer.

Journal of medicinal chemistry·2026

Related Experiment Video

Updated: Feb 19, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K

Dendrimer-based contrast agents for PET imaging.

Lingzhou Zhao1, Xiangyang Shi2,3, Jinhua Zhao1

  • 1a Department of Nuclear Medicine , Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine , Shanghai , People's Republic of China.

Drug Delivery
|November 11, 2017
PubMed
Summary
This summary is machine-generated.

Dendrimers serve as versatile scaffolds for developing positron emission tomography (PET) imaging agents. This review highlights recent advances in dendrimer-based PET agents for disease diagnosis and monitoring.

Keywords:
DendrimersPETcontrast agentpositron isotoperadiolabeling

More Related Videos

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Related Experiment Videos

Last Updated: Feb 19, 2026

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging
11:27

Preparation and In Vitro Characterization of Dendrimer-based Contrast Agents for Magnetic Resonance Imaging

Published on: December 4, 2016

10.6K
Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging
13:21

Preparation, Purification, and Characterization of Lanthanide Complexes for Use as Contrast Agents for Magnetic Resonance Imaging

Published on: July 21, 2011

15.4K
MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent
06:54

MR Molecular Imaging of Prostate Cancer with a Small Molecular CLT1 Peptide Targeted Contrast Agent

Published on: September 3, 2013

11.8K

Area of Science:

  • Nanotechnology
  • Medical Imaging
  • Radiochemistry

Background:

  • Positron emission tomography (PET) imaging provides crucial physiological and biological data for disease management.
  • Dendrimers, with their modifiable structures, are ideal scaffolds for creating novel PET imaging agents.
  • Significant progress has been achieved in dendrimer-based PET agent development over recent decades.

Purpose of the Study:

  • To review recent advancements in dendrimer-based contrast agents for PET imaging.
  • To focus on applications in cancer, cardiovascular, and other diseases.
  • To detail radiolabeling strategies for various PET isotopes.

Main Methods:

  • Literature review of recent research on dendrimer-based PET imaging agents.
  • Analysis of radiolabeling techniques for different PET isotopes.
  • Discussion of challenges in clinical translation.

Main Results:

  • Dendrimers enable the facile modification of targeting ligands and radionuclides for PET agent development.
  • Recent breakthroughs have expanded the use of dendrimer-based agents across various diseases.
  • Specific radiolabeling strategies for key PET isotopes have been detailed.

Conclusions:

  • Dendrimer-based agents represent a promising platform for advanced PET imaging.
  • Further research into radiolabeling and clinical translation is necessary for broader application.
  • These agents hold potential for improved disease diagnosis, therapy monitoring, and prognosis evaluation.